Status:
NOT_YET_RECRUITING
Comparison of Different Surgical Approaches in Female Rectal Cancer.
Lead Sponsor:
First Affiliated Hospital of Wenzhou Medical University
Collaborating Sponsors:
Wuhan TongJi Hospital
Zhejiang Cancer Hospital
Conditions:
Rectal Cancer Surgery
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Mid-to-low rectal cancer exhibits an extremely high incidence rate in China. Currently, the primary treatment approach for mid-to-low rectal cancer remains surgical intervention, with total mesorectal...
Eligibility Criteria
Inclusion
- Pathologically confirmed rectal adenocarcinoma.
- Female patients scheduled to undergo laparoscopic total mesorectal excision (TME).
- Body mass index (BMI) ≤ 30 kg/m².
- Tumors with the distal margin located ≤ 10 cm from the anal verge.
- Absence of distant metastases (e.g., to the liver, lungs, or other organs).
Exclusion
- Presence of severe pre-existing comorbidities (e.g., significant hepatic, renal, cardiac, pulmonary, or coagulation dysfunction).
- History of malignancy in other organs.
- Patients requiring emergency surgery due to conditions such as acute perforation or obstruction.
- Intraoperative findings of tumor invasion into adjacent organs necessitating multivisceral resection or palliative resection.
- Previous history of anorectal or rectal surgery. 6Preoperative magnetic resonance imaging (MRI) indicating invasion of the anterior rectal wall.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2030
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07189780
Start Date
October 1 2025
End Date
August 1 2030
Last Update
September 24 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.